A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
01
02
2021
accepted:
21
04
2021
pubmed:
3
6
2021
medline:
21
9
2021
entrez:
2
6
2021
Statut:
ppublish
Résumé
Palmoplantar pustulosis (PPP) is a chronic skin disease with painful erythematous scaly or crusty lesions and pustules on the palms and soles. Apremilast is a phosphodiesterase 4 inhibitor that has proven effective in the therapy of psoriasis, psoriatic arthritis and in oral ulcers associated with Behcet's disease. To explore the efficacy of apremilast in PPP. APLANTUS was a phase 2 single-arm multicentre study of apremilast in 21 subjects with moderate-to-severe PPP. Primary endpoint was the per cent change of the Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) at week 20 compared to baseline. 20 weeks of oral treatment with apremilast in patients with moderate-to-severe PPP resulted in a significant decrease of the PPPASI with a median reduction of 57.1% (p < 0.001), and 61.9% of patients achieved at least a 50% improvement of the PPPASI relative to baseline. The total number of pustules per patient decreased significantly relative to baseline with 76.2% of patients achieving at least a 50% reduction in total pustules count at week 20. Improvement of PPP was also apparent in a significant decrease of the dermatologic life quality index (DLQI). The median DLQI score dropped from 8.5 at baseline to 2.0 at week 20 (p = 0.030). Apremilast was generally well tolerated, and no serious adverse events occurred. Patients with PPP treated with apremilast showed benefit both in objective and subjective disease parameters. Apremilast should be investigated further in this difficult-to-treat skin condition. EudraCT number: 2016-005122-11.
Sections du résumé
BACKGROUND
BACKGROUND
Palmoplantar pustulosis (PPP) is a chronic skin disease with painful erythematous scaly or crusty lesions and pustules on the palms and soles. Apremilast is a phosphodiesterase 4 inhibitor that has proven effective in the therapy of psoriasis, psoriatic arthritis and in oral ulcers associated with Behcet's disease.
OBJECTIVE
OBJECTIVE
To explore the efficacy of apremilast in PPP.
METHODS
METHODS
APLANTUS was a phase 2 single-arm multicentre study of apremilast in 21 subjects with moderate-to-severe PPP. Primary endpoint was the per cent change of the Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) at week 20 compared to baseline.
RESULTS
RESULTS
20 weeks of oral treatment with apremilast in patients with moderate-to-severe PPP resulted in a significant decrease of the PPPASI with a median reduction of 57.1% (p < 0.001), and 61.9% of patients achieved at least a 50% improvement of the PPPASI relative to baseline. The total number of pustules per patient decreased significantly relative to baseline with 76.2% of patients achieving at least a 50% reduction in total pustules count at week 20. Improvement of PPP was also apparent in a significant decrease of the dermatologic life quality index (DLQI). The median DLQI score dropped from 8.5 at baseline to 2.0 at week 20 (p = 0.030). Apremilast was generally well tolerated, and no serious adverse events occurred.
CONCLUSIONS
CONCLUSIONS
Patients with PPP treated with apremilast showed benefit both in objective and subjective disease parameters. Apremilast should be investigated further in this difficult-to-treat skin condition. EudraCT number: 2016-005122-11.
Substances chimiques
Phosphodiesterase 4 Inhibitors
0
Thalidomide
4Z8R6ORS6L
apremilast
UP7QBP99PN
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2045-2050Informations de copyright
© 2021 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol 2020; 21: 355-370.
Wilsmann-Theis D, Jacobi A, Frambach Y et al. Palmoplantar pustulosis - a cross-sectional analysis in Germany. Dermatol Online J 2017; 23.
Schafer PH, Parton A, Capone L et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal 2014; 26: 2016-2029.
Carrascosa de Lome R, Conde Montero E. La Cueva Dobao P de. Refractory palmoplantar pustulosis succesfully treated with apremilast. Dermatol Ther 2020; 33: e13230.
Eto A, Nakao M, Furue M. Three cases of palmoplantar pustulosis successfully treated with apremilast. J Dermatol 2019; 46: e29-e30.
Haebich G, Kalavala M. Successful treatment of refractory palmoplantar pustulosis with apremilast. Clin Exp Dermatol 2017; 42: 471-473.
Kromer C, Wilsmann-Theis D, Gerdes S et al. Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study. J Dtsch Dermatol Ges 2019; 17: 503-516.
Bhushan M, Burden AD, McElhone K et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2001; 145: 546-553.
Haynes D, Strunck JL, Topham CA et al. Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris. JAMA Dermatol 2020; 156: 668.
Hongbo Y, Thomas CL, Harrison MA et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659-664.
Terui T, Kobayashi S, Okubo Y et al. Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial. JAMA Dermatol 2018; 154: 309-316.
Terui T, Kobayashi S, Okubo Y et al. Efficacy and safety of guselkumab in japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial. JAMA Dermatol 2019; 155: 1153.
Puig L. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert Rev Clin Immunol 2019; 15: 589-597.
Hatemi G, Mahr A, Ishigatsubo Y et al. Trial of apremilast for oral ulcers in Behçet's syndrome. N Engl J Med 2019; 381: 1918-1928.
Irla N, Navarini AA, Yawalkar N. Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis. Br J Dermatol 2012; 167: 1170-1174.
Mrowietz U, Bachelez H, Burden AD et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol 2019; 80: 1344-1352.